Shelter Pharma (543963) Q2 25/26 earnings summary

Executive summary

• Standalone unaudited financial results for the half year ended 30th September 2025 were approved and reviewed by the Board and auditors.

• No material misstatements or deviations were identified in the financial statements as per the limited review report.

Financial highlights

• Revenue from operations for the half year ended 30th September 2025 was ₹3,329.29 lakhs, up from ₹2,405.67 lakhs in the same period last year.

• Net profit for the half year was ₹450.07 lakhs, compared to ₹353.64 lakhs year-over-year.

• Basic and diluted EPS for the period stood at ₹3.89, up from ₹3.06 year-over-year.

• Cash and cash equivalents increased to ₹527.96 lakhs as of 30th September 2025 from ₹341.99 lakhs at the end of the previous year.

Outlook and guidance

• The company continues to focus on pharmaceutical manufacturing as its primary business segment.